Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas

References

1. 1.↵
   2. Dhermain FG,
   3. Hau P,
   4. Lanfermann H, et al

   . Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9:906–20 doi:10.1016/S1474-4422(10)70181-2 pmid:20705518

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Brandes AA,
   3. Franceschi E,
   4. Tosoni A, et al

   . MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192–97 doi:10.1200/JCO.2007.14.8163 pmid:18445844

   Abstract/FREE Full Text
3. 3.↵
   2. Taal W,
   3. Brandsma D,
   4. de Bruin HG, et al

   . Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405–10 doi:10.1002/cncr.23562 pmid:18484594

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Wen PY,
   3. Macdonald DR,
   4. Reardon DA, et al

   . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

   Abstract/FREE Full Text
5. 5.↵
   2. Chinot OL,
   3. Macdonald DR,
   4. Abrey LE, et al

   . Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 2013;13:347 doi:10.1007/s11910-013-0347-2 pmid:23529375

   CrossRefPubMed
6. 6.↵
   2. Chinot OL,
   3. Wick W,
   4. Mason W, et al

   . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709–22 doi:10.1056/NEJMoa1308345 pmid:24552318

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Warren KE,
   3. Poussaint TY,
   4. Vezina G, et al

   . Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer 2013;60:1397–401 doi:10.1002/pbc.24562 pmid:23625747

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Kang TW,
   3. Kim ST,
   4. Byun HS, et al

   . Morphological and functional MRI, MRS, perfusion and diffusion changes after radiosurgery of brain metastasis. Eur J Radiol 2009;72:370–80 doi:10.1016/j.ejrad.2008.08.009 pmid:18829196

   CrossRefPubMed
9. 9.↵
   2. Cha J,
   3. Kim ST,
   4. Kim HJ, et al

   . Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression. Eur Radiol 2013;23:879–86 doi:10.1007/s00330-012-2638-4 pmid:22903642

   CrossRefPubMed
10. 10.↵
    2. Lee WJ,
    3. Choi SH,
    4. Park CK, et al

    . Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. Acad Radiol 2012;19:1353–61 doi:10.1016/j.acra.2012.06.011 pmid:22884399

    CrossRefPubMed
11. 11.↵
    2. Chang YW,
    3. Yoon HK,
    4. Shin HJ, et al

    . MR imaging of glioblastoma in children: usefulness of diffusion/perfusion-weighted MRI and MR spectroscopy. Pediatr Radiol 2003;33:836–42 doi:10.1007/s00247-003-0968-8 pmid:14564423

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Batchelor TT,
    3. Gerstner ER,
    4. Emblem KE, et al

    . Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 2013;110:19059–64 doi:10.1073/pnas.1318022110 pmid:24190997

    Abstract/FREE Full Text
13. 13.↵
    2. Nasseri M,
    3. Gahramanov S,
    4. Netto JP, et al

    . Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro Oncol 2014;16:1146–54 doi:10.1093/neuonc/not328 pmid:24523362

    Abstract/FREE Full Text
14. 14.↵
    2. Bag AK,
    3. Cezayirli PC,
    4. Davenport JJ, et al

    . Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. J Neurooncol 2014;120:361–70 doi:10.1007/s11060-014-1560-9 pmid:25098699

    CrossRefPubMed
15. 15.↵
    2. Ratai EM,
    3. Zhang Z,
    4. Snyder BS, et al

    . Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro Oncol 2013;15:936–44 doi:10.1093/neuonc/not044 pmid:23645534

    Abstract/FREE Full Text
16. 16.↵
    2. Orphanidou-Vlachou E,
    3. Auer D,
    4. Brundler MA, et al

    . (1)H magnetic resonance spectroscopy in the diagnosis of paediatric low grade brain tumours. Eur J Radiol 2013;82:e295–301 doi:10.1016/j.ejrad.2013.01.030 pmid:23489978

    CrossRefPubMed
17. 17.↵
    2. Quon H,
    3. Brunet B,
    4. Alexander A, et al

    . Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapy. Anticancer Res 2011;31:3559–65 pmid:21965778

    Abstract/FREE Full Text
18. 18.↵
    Clinical Trial Imaging Endpoint Process Standards Guidance for Industry (Draft Guidance March 2015). http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm268555.pdf. Accessed October 19, 2015.
19. 19.↵
    2. Ellingson BM,
    3. Bendszus M,
    4. Boxerman J, et al

    ; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol 2015;17:1188–98 doi:10.1093/neuonc/nov095 pmid:26250565

    Abstract/FREE Full Text
20. 20.↵
    2. Ellingson BM,
    3. Kim HJ,
    4. Woodworth DC, et al

    . Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 2014;271:200–10 doi:10.1148/radiol.13131305 pmid:24475840

    CrossRefPubMedWeb of Science